Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
This phase II trial will investigate the efficacy and safety of the addition of Optune (Tumor
Treating Fields [TTFields] Therapy) to bevacizumab for patients with bevacizumab-refractory
recurrent glioblastoma.